-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
VEGF is an important factor in the process of angiogenesis, and it is over-expressed pathologically in most human tumor endothelial cells
.
Anti-VEGF antibodies can selectively bind to VEGF with high affinity.
By blocking the binding of VEGF to its receptors on the surface of vascular endothelial cells, it blocks the conduction of PI3K-Akt/PKB and Ras-Raf-MEK-ERK signaling pathways, thereby Inhibit the growth, proliferation, migration and angiogenesis of vascular endothelial cells, reduce vascular permeability, block the blood supply of tumor tissues, inhibit tumor cell proliferation and metastasis, and induce tumor cell apoptosis, thereby achieving anti-tumor therapeutic effects
.
In the domestic ophthalmic drug market, because anti-VEGF drugs can effectively inhibit the formation of new blood vessels and promote the regression of existing new blood vessels, these drugs have also become the main means of fundus vascular diseases.
The currently approved anti-VEGF antibody drugs are all Monospecific antibodies, among them, ranibizumab, conbercept and aflibercept, the three major antibody products, occupy a huge market segment
.
It is reported that these three drugs together accounted for more than 99% of the market share in 2018
.
In 2019, three products successfully entered Category B of the National Medical Insurance Catalogue
.
As of 2019, the share of conbercept and ranibizumab in the domestic market is about 50%
.
With the intensification of aging, changes in living habits and faster pace of life, the number of patients with various ophthalmological diseases continues to increase, and it is expected that China's ophthalmic medicine market will usher in a major outbreak
.
The scale of anti-VEGF drugs in the ophthalmic drug market is huge, and there are opportunities to be tapped
.
Data show that the scale of domestic anti-VEGF drugs reached 4.
75 billion yuan in 2019.
In 2017, the ophthalmic penetration rate of such drugs was only 1.
15%.
It is expected that this penetration rate can increase to 5.
65% by 2025
.
In addition, according to the research report of the securities firm, it is assumed that by 2025, the penetration rate and frequency of use of VEGF drugs in ophthalmology in China will reach the level of the United States, and the market space for VEGF drugs in ophthalmology in China will exceed 10 billion by then
.
In the face of such a huge market blue ocean, the domestic ophthalmic VEGF antibody drug market is ushering in more and more disruptors
.
In recent news, Osaikang issued an announcement stating that the company’s application for clinical trials of the new drug ASKG712 for injection has been accepted.
The product is intended to treat a variety of retinal diseases such as AMD (age-related macular degeneration), DME (diabetic macular edema) and RVO -ME (secondary to branch retinal vein occlusion macular edema) and the like
.
It is understood that ASKG712 for injection is a dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitory peptide fusion protein with independent intellectual property rights developed by the company
.
Unlike the current DME and nAMD treatments that inhibit the VEGF pathway, this product targets two different pathways-through Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor A (VEGF-A)
.
By blocking these two pathways at the same time, the efficacy of the drug in stabilizing blood vessels will be more prominent, and it can reduce inflammation and leakage more than inhibiting either approach alone
.
Compared with the monoclonal antibody VEGF therapy, bispecific antibody therapy is expected to improve the efficacy of vision improvement, thereby reducing the frequency of eye injections required, reducing the burden of treatment for doctors and patients, and improving patient compliance
.
The industry believes that Aosaikang has achieved the first domestic declaration of VEGF/Ang-2 dual antibodies, and is expected to seize an advantageous position in this subdivision track
.
It is worth mentioning that there are still more than a dozen new anti-VEGF drugs under development.
It is expected that the market competition will be very fierce in the future
.
.
Anti-VEGF antibodies can selectively bind to VEGF with high affinity.
By blocking the binding of VEGF to its receptors on the surface of vascular endothelial cells, it blocks the conduction of PI3K-Akt/PKB and Ras-Raf-MEK-ERK signaling pathways, thereby Inhibit the growth, proliferation, migration and angiogenesis of vascular endothelial cells, reduce vascular permeability, block the blood supply of tumor tissues, inhibit tumor cell proliferation and metastasis, and induce tumor cell apoptosis, thereby achieving anti-tumor therapeutic effects
.
In the domestic ophthalmic drug market, because anti-VEGF drugs can effectively inhibit the formation of new blood vessels and promote the regression of existing new blood vessels, these drugs have also become the main means of fundus vascular diseases.
The currently approved anti-VEGF antibody drugs are all Monospecific antibodies, among them, ranibizumab, conbercept and aflibercept, the three major antibody products, occupy a huge market segment
.
It is reported that these three drugs together accounted for more than 99% of the market share in 2018
.
In 2019, three products successfully entered Category B of the National Medical Insurance Catalogue
.
As of 2019, the share of conbercept and ranibizumab in the domestic market is about 50%
.
With the intensification of aging, changes in living habits and faster pace of life, the number of patients with various ophthalmological diseases continues to increase, and it is expected that China's ophthalmic medicine market will usher in a major outbreak
.
The scale of anti-VEGF drugs in the ophthalmic drug market is huge, and there are opportunities to be tapped
.
Data show that the scale of domestic anti-VEGF drugs reached 4.
75 billion yuan in 2019.
In 2017, the ophthalmic penetration rate of such drugs was only 1.
15%.
It is expected that this penetration rate can increase to 5.
65% by 2025
.
In addition, according to the research report of the securities firm, it is assumed that by 2025, the penetration rate and frequency of use of VEGF drugs in ophthalmology in China will reach the level of the United States, and the market space for VEGF drugs in ophthalmology in China will exceed 10 billion by then
.
In the face of such a huge market blue ocean, the domestic ophthalmic VEGF antibody drug market is ushering in more and more disruptors
.
In recent news, Osaikang issued an announcement stating that the company’s application for clinical trials of the new drug ASKG712 for injection has been accepted.
The product is intended to treat a variety of retinal diseases such as AMD (age-related macular degeneration), DME (diabetic macular edema) and RVO -ME (secondary to branch retinal vein occlusion macular edema) and the like
.
It is understood that ASKG712 for injection is a dual-targeting anti-VEGF-A humanized monoclonal antibody-Ang-2 inhibitory peptide fusion protein with independent intellectual property rights developed by the company
.
Unlike the current DME and nAMD treatments that inhibit the VEGF pathway, this product targets two different pathways-through Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor A (VEGF-A)
.
By blocking these two pathways at the same time, the efficacy of the drug in stabilizing blood vessels will be more prominent, and it can reduce inflammation and leakage more than inhibiting either approach alone
.
Compared with the monoclonal antibody VEGF therapy, bispecific antibody therapy is expected to improve the efficacy of vision improvement, thereby reducing the frequency of eye injections required, reducing the burden of treatment for doctors and patients, and improving patient compliance
.
The industry believes that Aosaikang has achieved the first domestic declaration of VEGF/Ang-2 dual antibodies, and is expected to seize an advantageous position in this subdivision track
.
It is worth mentioning that there are still more than a dozen new anti-VEGF drugs under development.
It is expected that the market competition will be very fierce in the future
.
